Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Overview | Financials
Company Name | Rigel Pharmaceuticals, Inc. |
Symbol | RIGL |
Currency | USD |
Price | 16.44 |
Market Cap | 289,590,600 |
Dividend Yield | 0% |
52-week-range | 7.48 - 29.82 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Raul R. Rodriguez |
Website | https://www.rigel.com |
An error occurred while fetching data.
About Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD